ROG Panoramica delle azioni Roche Holding AG opera nel settore farmaceutico e diagnostico in Europa, Nord America, America Latina, Asia, Africa, Australia e Oceania. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Roche Holding AG Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Roche Holding Prezzi storici delle azioni Prezzo attuale dell'azione CHF 255.00 Massimo di 52 settimane CHF 288.20 Minimo di 52 settimane CHF 212.90 Beta 0.14 Variazione di 1 mese 0.59% Variazione a 3 mesi -4.67% Variazione di 1 anno 4.72% Variazione a 3 anni -32.59% Variazione a 5 anni -19.18% Variazione dall'IPO 877.01%
Notizie e aggiornamenti recenti
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25
Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks Nov 25 Vedi altri aggiornamenti
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25
Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks Nov 25
Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024 Nov 05
Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease Nov 02 Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials
Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study Oct 14
FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation Oct 11 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Sep 13
These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well Sep 10 Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis Sep 04
Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH Aug 27
New minor risk - Earnings quality Aug 02
European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO) Jul 30
First half 2024 earnings: EPS misses analyst expectations Jul 28
Roche Holding AG Raises Earnings Guidance for the Year 2024 Jul 25
BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche Jul 23 New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD) Jul 09
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer Jul 04
Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024 Jun 26
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Jun 25
Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma Jun 20 Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma Jun 17
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant May 31
Roche Announces Management and Board Committee Changes May 28
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) May 25
Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity May 18
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer May 16
Roche Holding AG Provides Earnings Guidance for the Year 2024 Apr 24 FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer Apr 20
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab) Apr 17
We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt Apr 17 Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis Apr 12
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors Mar 27 Roche Holding AG, Annual General Meeting, Mar 12, 2024 Mar 13
Upcoming dividend of CHF9.60 per share Mar 07
Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year Mar 06
Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension Mar 05
Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Feb 17
Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need Feb 12
Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year Feb 09
Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear Feb 08
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 07
Dividend increased to CHF9.60 Feb 04
Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO) Feb 02 Roche Holding AG Proposes Dividend
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 30
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 29
European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types Jan 16
Market Cool On Roche Holding AG's (VTX:ROG) Earnings Dec 29
Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024 Dec 20
Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition Dec 12
Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A Dec 11 Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion. Dec 04
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 29
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 28
Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List Nov 18 Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types Nov 17
Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration Nov 09 Rendimenti per gli azionisti ROG CH Pharmaceuticals CH Mercato 7D -0.4% 0.1% -0.5% 1Y 4.7% 5.4% 2.8%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: ROG ha trovato corrispondenza nel Swiss Pharmaceuticals che ha restituito 5.4 % nell'ultimo anno.
Rendimento vs Mercato: ROG ha superato il mercato Swiss che ha restituito 2.8 % nell'ultimo anno.
Volatilità dei prezzi Is ROG's price volatile compared to industry and market? ROG volatility ROG Average Weekly Movement 2.1% Pharmaceuticals Industry Average Movement 3.1% Market Average Movement 3.3% 10% most volatile stocks in CH Market 7.4% 10% least volatile stocks in CH Market 1.6%
Prezzo delle azioni stabile: ROG non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 2% ) di ROG è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1896 103,605 Thomas Schinecker www.roche.com
Roche Holding AG opera nel settore farmaceutico e diagnostico in Europa, Nord America, America Latina, Asia, Africa, Australia e Oceania. L'azienda offre prodotti farmaceutici nelle aree terapeutiche dell'anemia, dei tumori del sangue e solidi, della dermatologia, dell'emofilia, delle malattie infiammatorie e autoimmuni, dei disturbi neurologici, dell'oftalmologia, dei disturbi respiratori e dei trapianti. L'azienda sta inoltre sviluppando prodotti per diverse aree terapeutiche.
Mostra di più Roche Holding AG Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Roche Holding con la sua capitalizzazione di mercato? ROG statistiche fondamentali Capitalizzazione di mercato CHF 204.87b Guadagni(TTM ) CHF 10.62b Ricavi(TTM ) CHF 60.58b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) ROG Conto economico (TTM ) Ricavi CHF 60.58b Costo del fatturato CHF 15.43b Profitto lordo CHF 45.16b Altre spese CHF 34.54b Guadagni CHF 10.62b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 13.33 Margine lordo 74.54% Margine di profitto netto 17.53% Rapporto debito/patrimonio netto 104.8%
Come si è comportato ROG nel lungo periodo?
Vedi performance storica e confronto Dividendi
3.8% Rendimento attuale del dividendo
72% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/18 12:07 Prezzo dell'azione a fine giornata 2024/12/18 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Roche Holding AG è coperta da 61 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Kamla Singh AlphaValue John Staszak Argus Research Company Gerhard Schwarz Baader Helvea Equity Research
Mostra 58 altri analisti 
